PHENTERMINE HYDROCHLORIDE tablet PHENTERMINE HYDROCHLORIDE capsule

Country: Amerika Syarikat

Bahasa: Inggeris

Sumber: NLM (National Library of Medicine)

Bahan aktif:

PHENTERMINE HYDROCHLORIDE (UNII: 0K2I505OTV) (PHENTERMINE - UNII:C045TQL4WP)

Boleh didapati daripada:

Blenheim Pharmacal, Inc.

INN (Nama Antarabangsa):

PHENTERMINE HYDROCHLORIDE

Komposisi:

PHENTERMINE HYDROCHLORIDE 37.5 mg

Laluan pentadbiran:

ORAL

Jenis preskripsi:

PRESCRIPTION DRUG

Tanda-tanda terapeutik:

Phentermine hydrochloride, USP 37.5 mg is indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index ≥30 kg/m2 , or≥27 kg/m2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia). Below is a chart of Body Mass Index (BMI) based on various heights and weights. BMI is calculated by taking the patient’s weight, in kilograms (kg), divided by the patient’s height, in meters (m), squared. Metric conversions are as follows: pounds ÷ 2.2 = kg; inches x 0.0254 = meters. The limited usefulness of agents of this class, including Phentermine hydrochloride, [see CLINICAL PHARMACOLOGY ( 12.1 , 12.2 ) ] should be measured against possible risk factors inherent in their use such as those described below. •History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart fail

Ringkasan produk:

Available in tablets and capsules containing 37.5 mg phentermine hydrochloride (equivalent to 30 mg Phentermine base). Phentermine hydrochloride capsules, USP 37.5 mg are supplied as bright blue opaque cap, white opaque body with black imprint “K 29” on both cap and body, filled with powder. Bottles of 30, NDC 10702-029-03 Bottles of 100, NDC 10702-029-01 Bottles of 1000, NDC 10702-029-10 Phentermine hydrochloride tablets, USP 37.5 mg (equivalent to 30 mg phentermine base), are supplied as blue and white mottled oval tablets debossed “K” left to bisect “25” on one side and plain on the other side. Bottles of 30, NDC 10702-025-03 Bottles of 100, NDC 10702-025-01 Bottles of 1000, NDC 10702-025-10 Store at 20° to 25°C (68° to 77°F), with excursions permitted between 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Dispense in a tight container as defined in the USP/NF, with a child-resistant closure (as required). Keep out of the reach of children

Status kebenaran:

Abbreviated New Drug Application

Ciri produk

PHENTERMINE HYDROCHLORIDE- PHENTERMINE HYDROCHLORIDE TABLET
PHENTERMINE HYDROCHLORIDE- PHENTERMINE HYDROCHLORIDE CAPSULE
BLENHEIM PHARMACAL, INC.
----------
UNKNOWN TITLE
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
PHENTERMINE HYDROCHLORIDE
TABLETS AND CAPSULES, USP 37.5 MG SAFELY AND EFFECTIVELY. SEE FULL
PRESCRIBING INFORMATION FOR
PHENTERMINE HYDROCHLORIDE TABLETS AND CAPSULES, USP 37.5 MG.
PHENTERMINE HYDROCHLORIDE TABLETS AND CAPSULES , USP 37.5 MG
(PHENTERMINE HYDROCHLORIDE
USP) CIV FOR ORAL USE
INDICATIONS AND USAGE
Phentermine hydrochloride is a sympathomimetic amine anorectic
indicated as a short-term adjunct (a
few weeks) in a regimen of weight reduction based on exercise,
behavioral modification and caloric
restriction in the management of exogenous obesity for patients with
an initial body mass index ≥ 30
kg/m , or ≥ 27 kg/m in the presence of other risk factors (e.g.,
controlled hypertension, diabetes,
hyperlipidemia). (1)
The limited usefulness of agents of this class, including Phentermine
hydrochloride, should be
measured against possible risk factors inherent in their use. (1)
DOSAGE AND ADMINISTRATION
• Dosage should be individualized to obtain an adequate response
with the lowest effective dose. (2)
• Late evening administration should be avoided (risk of insomnia).
(2)
• Phentermine hydrochloride can be taken with or without food.
(12.3)
DOSAGE FORMS AND STRENGTHS
• Capsules containing 37.5 mg phentermine hydrochloride. (3)
• Tablets containing 37.5 mg phentermine hydrochloride. (3)
CONTRAINDICATIONS
• History of cardiovascular disease (e.g., coronary artery disease,
stroke, arrhythmias, congestive heart
failure, uncontrolled hypertension) (4)
• During or within 14 days following the administration of monoamine
oxidase inhibitors (4)
• Hyperthyroidism (4)
• Glaucoma (4)
• Agitated states (4)
• History of drug abuse (4)
• Pregnancy (4, 8.1)
• Nursing (4, 8.3)
• Known hypersensitivity, or idiosyncrasy to